AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin.
OBJECTIVE
To evaluate efficacy and tolerance of bleomycin in AIDS-associated mucocutaneous Kaposi's sarcoma. A previous study showed that bleomycin was effective and well tolerated in this setting.


METHODS
A non-comparative, open, prospective study.


METHODS
Seventy patients were treated with 5 mg per day intramuscular bleomycin on 3 consecutive days every 2 weeks.


RESULTS
Two patients achieved a complete response and 50 a partial response (overall response rate, 74%). Median time to treatment response was 4 weeks (range, 2-12 weeks) and median time to relapse 10 weeks (range, 2-36 weeks). Dose-limiting toxicity consisted of cutaneous adverse reactions.


CONCLUSIONS
Bleomycin is active against AIDS-associated mucocutaneous Kaposi's sarcoma; relapse occurs after discontinuation of therapy.
Caumes
E
E
Département de Médecine Tropicale, Maladies Infectieuses, Parasitologie, Mycologie et Santé Publique, Hôpital de la Salpêtrière, Paris, France.
Guermonprez
G
G
Katlama
C
C
Gentilini
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D001761:Bleomycin / Q000627:therapeutic use* / Q000633:toxicity; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D016019:Survival Analysis; D016896:Treatment Outcome
D001761:Bleomycin